Genetic studies and Mendelian randomization analyses have further supported the role of PCSK9 in AAA pathogenesis and identified the opportunity for repurposing PCSK9 inhibitors to mitigate AAA growth and reduce cardiovascular risks in affected individuals [119, 120]. Here, PCSK9 is linked to triple-A syndrome.